Sermorelin is a synthetic research peptide consisting of the first 29 amino acids of naturally occurring human growth hormone-releasing hormone (GHRH). This sequence represents the biologically active portion of GHRH and has become widely studied in laboratory research involving pituitary signaling, growth hormone regulation, neuroendocrine communication, and the growth hormone/insulin-like growth factor-1 (IGF-1) axis.

Sermorelin research has explored its interaction with GHRH receptors located on somatotroph cells within the anterior pituitary. Researchers have investigated the receptor-mediated signaling mechanisms associated with growth hormone synthesis and release, as well as the physiological regulation of pulsatile growth hormone activity.

Another significant area of Sermorelin research involves downstream growth hormone and IGF-1 signaling. Laboratory studies have examined these pathways in relation to cellular metabolism, protein synthesis, tissue signaling, and other biological processes regulated through the growth hormone axis.

Sermorelin has a molecular weight of approximately 3,358 g/mol and is synthetically produced for controlled research applications. It is typically supplied as a white, lyophilized powder for laboratory investigation involving GHRH receptor biology, pituitary signaling, and related neuroendocrine pathways.